Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer.

ABSTRACT:

Purpose

To investigate the safety, activity, and potential biomarkers of response to olaparib and carboplatin combination in sporadic triple negative breast cancer (TNBC). EXPERIMENTAL DESIGN: Metastatic or recurrent TNBC patients with no germline BRCA mutation or with BRCAPro scores <10% and a negative family history were eligible. A 3+3 dose escalation tested olaparib capsules (400mg bid, days1-7) with carboplatin AUC3-5 on day1 or 2 every 21 days, ≤ 8 cycles, with olaparib 400mg bid maintenance. Peripheral blood mononuclear cells were collected for polymorphisms and PAR levels, and paired tumor biopsies (pre-/post-cycle 1) for proteomics and apoptosis endpoints.

Results

28 women were treated (median 5 prior regimens [0-12]). Dose-limiting toxicity was thrombocytope

SUBMITTER: Lee JM 

PROVIDER: S-EPMC5668030 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature